7:50 am REGISTRATION & MORNING COFFEE
8:50 am Chair’s Opening Remarks
9:00 am Exploring Novel Innovation to Meet Significant Unmet Needs in Post-Traumatic Stress Disorder & Autism Spectrum Disorder
Synopsis
- Reviewing the current developmental landscape for treatment of neuropsychiatric symptoms in PTSD and ASD
- Outlining where we have seen evidence of progress and where the field must improve
- Uncovering significant learnings from past failings and optimistic implications for the future
RECAPITULATING PSYCHIATRIC CONDITIONS IN PRECLINICAL MODEL SYSTEMS
9:30 am Panel Discussion: Evaluating the Current Ability for Preclinical Models & Biomarkers to Translate Psychiatric Programs into the Clinic
Synopsis
- Critically analyzing animal models for accelerating translational development of psychedelic and non-psychedelic compounds
- Deciphering the most promising preclinical systems for assessing therapeutic durability
- Exploring the advantages and limitations of in vitro models for investigating potential drugs to target mental health disorders
10:20 am Session Reserved for PsychoGenics
10:30 am MORNING BREAK & REFRESHMENTS
11:00 am Exploring Beyond Head Twitch Response Assays to Effectively Monitor Psychedelic Therapeutics In Vivo
Synopsis
- Investigating the ability of animal models to measure the durability of psychedelic compounds
- Establishing more objective monitoring of psychiatric conditions in animals to revolutionize preclinical understanding of psychedelic mechanisms of action and therapeutic effects
- Optimizing imaging and EEG studies in in vivo models to distinguish between hallucinogenic and non-hallucinogenic molecules
11:30 am Using Machine-Learning to Enable High Throughput Development of New Therapies for Neuropathic & Nociplastic Pain
Synopsis
Utilizing proprietary AI algorithms to interpret experimental animal behavioral data to
understand how psychedelics affect the psychological aspects of pain and how they work
to promote neuroplasticity in pain circuitry.
12:00 pm LUNCH & NETWORKING BREAK
MANAGING EVOLVING REGULATORY GUIDELINES & ACCEPTANCE WHEN ENTERING A COMPETITIVE NEUROPSYCHIATRIC MARKET
1:00 pm Roundtable Discussion: Navigating the Evolving Regulatory Landscape for Antipsychotic Treatments of Psychiatric Disorders
Synopsis
More practical and highly interactive breakout roundtables where attendees can crowd-source solutions and share opinions around pre-assigned topic areas:
- Due to the intense effects of psychedelics, how can sponsors address this challenge to optimize signal detection? Are there special considerations for shorter acting vs longer acting psychedelics?
- How can psychiatric assessments be improved to enhance confidence of efficacy and mitigate safety concerns among regulators?
- How can we overcome the bias nature of psychedelics and standardize preparation and observation guidelines?
Moderator Feedback & Audience Debate
Moderators will be assigned to each roundtable to facilitate discussion and collate the findings. Following the roundtable discussions, they will present back to the entire delegation and open up wider audience debate.
EXPLORING DISCOVERY TECHNQIUES & KNOWLEDGE ADVANCES TO IDENTIFY MORE EFFICACOUS TARGETS
1:45 pm Emerging Genetics of Psychiatric disorders Enables Next-Generation Therapeutics to Target Dysfunctional circuits in the Brain
Synopsis
- Studying sleep and wake neurophysiology in human patients and animal models
- Deepening understanding of correlations between sleep physiology and neurocircuit to identify targets for novel psychiatric therapies
2:15 pm AFTERNOON BREAK & NETWORKING COFFEE
2:45 pm Employing Human Genetics for Discovery in the Psychiatric Disease Area
Synopsis
- Building genetic databases, with a focus on exomes, for gene discovery in psychiatric disease
- Exploring genetic risk factors shared across disorders that may reflect shared symptoms
3:15 pm Novel Discoveries of Psychedelic Medicines for Neuropsychiatry: Where Are We Now & Where Are We Headed
Synopsis
- Overview of the current psychedelic drug development landscape for psychiatric disorders
- Understanding the neurobiological, pharmacologic, and circuit mechanisms mediating the therapeutic effects of psychedelics.
- Psychedelic-mediated modulation of glial plasticity: implications for drug discovery
3:45 pm Translating Genetics & Basic Research into Drug Discovery Projects to Innovate Mechanistic-Based Treatments in Neuropsychiatry
Synopsis
- From risk genes to understanding mechanisms driving neural circuit activity, behaviour, and
- potential therapeutic
- The development of assays and tools to study disease pathophysiology, assess target engagement and therapeutic efficacy
- Diversity across cell types, species and patients